IBM is accelerating its efforts to build out its artificial intelligence infrastructure through a dual-track strategy of major acquisitions and key partnerships. Despite this aggressive strategic offensive, the market reaction has been notably tepid, with Wall Street analysts expressing caution and the company’s shares facing significant headwinds.
A Dual-Pronged Strategy for AI Expansion
The technology giant recently finalized the historic $11 billion acquisition of data specialist Confluent, marking its largest deal since the HashiCorp integration in 2024. In a nearly simultaneous move, IBM’s management announced an expanded collaboration with Nvidia at the GTC conference. Starting in the second quarter of 2026, IBM Cloud will offer Nvidia’s new Blackwell Ultra GPUs for large-scale AI model training.
Early results from this combined hardware and software approach are already visible. In an initial project with Nestlé, the integration of Nvidia hardware and IBM software reportedly reduced the runtime of complex data queries from 15 minutes to just three, leading to cost savings of 83 percent for the consumer goods company.
Lingering Concerns from a Market Shock
These operational advancements, however, have done little to alleviate investor concerns rooted in a recent market event. In late February, IBM lost over $31 billion in market value in a single trading session. The trigger was an announcement from AI firm Anthropic regarding a new tool capable of modernizing legacy COBOL systems—a direct challenge to IBM’s lucrative mainframe business.
Should investors sell immediately? Or is it worth buying IBM?
While industry experts, including Gartner analyst Matt Brasier, assess the immediate threat as limited—citing that modernization costs for clients often outweigh the benefits—the fear of broader industry disruption persists. This anxiety continues to weigh on investor sentiment across the software sector, despite IBM’s existing portfolio of AI tools designed for COBOL environments.
Analyst Community Adopts a Cautious Stance
Reflecting this cautious environment, major investment banks have issued restrained assessments following the closure of the Confluent deal. Several analysts revised their price targets downward this week:
- BMO Capital Markets: Reduced target price from $350 to $290 (Rating: Market Perform)
- JPMorgan: Lowered target price from $317 to $283 (Rating: Neutral)
The equity’s performance mirrors this skepticism. With shares currently trading at 209.95 Euros, the stock has declined more than 15 percent since the start of the year.
The Path Forward: Integration and Execution
Moving forward, IBM faces the concrete challenge of rapidly integrating Confluent’s costly technology into its own ecosystem. Concurrently, the company must demonstrate in the ongoing second quarter that its new Nvidia-powered cloud capacities can translate into measurable market share gains. The success of these twin initiatives will be crucial in shifting the current narrative and rebuilding investor confidence.
Ad
IBM Stock: Buy or Sell?! New IBM Analysis from March 21 delivers the answer:
The latest IBM figures speak for themselves: Urgent action needed for IBM investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 21.
IBM: Buy or sell? Read more here...









